John R. Hyngstrom

Oncology

5121 S Cottonwood St
Murray, UT 84107

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 68 publications

Corrigendum to "The benefit of sentinel lymph node biopsy in elderly patients with melanoma: A retrospective analysis of SEER-Medicare data (2010-2018)" [Am J Surg 237 (2024) 115896].

Corrigendum to "The benefit of sentinel lymph node biopsy in elderly patients with melanoma: A retrospective analysis of SEER-Medicare data (2010-2018)" [Am J Surg 237 (2024) 115896].

Journal: American journal of surgery

Published: May 21, 2026

Therapy-induced androgen receptor signaling as a candidate upstream driver of B7-H3-linked immune exclusion in melanoma: mechanisms and translational opportunities.

Therapy-induced androgen receptor signaling as a candidate upstream driver of B7-H3-linked immune exclusion in melanoma: mechanisms and translational opportunities.

Journal: Frontiers in medicine

Published: February 09, 2026

ASO Visual Abstract: National Evaluation of the Management of Melanoma Patients with Multiple Positive Sentinel Lymph Nodes.

ASO Visual Abstract: National Evaluation of the Management of Melanoma Patients with Multiple Positive Sentinel Lymph Nodes.

Journal: Annals of surgical oncology

Published: November 03, 2025

Gene Expression Profile-Based Test to Predict Melanoma Sentinel Node Status: The MERLIN_001 Study.

Gene Expression Profile-Based Test to Predict Melanoma Sentinel Node Status: The MERLIN_001 Study.

Journal: JAMA surgery

Published: October 22, 2025

Longitudinal ctDNA Monitoring for Postsurgical Disease Surveillance in Patients with Stage I to IIIB Melanoma.

Longitudinal ctDNA Monitoring for Postsurgical Disease Surveillance in Patients with Stage I to IIIB Melanoma.

Journal: Clinical cancer research : an official journal of the American Association for Cancer Research

Published: October 02, 2025

Publisher Correction: Anti-PD-1 therapy in unresectable desmoplastic melanoma: the phase 2 SWOG S1512 trial.

Publisher Correction: Anti-PD-1 therapy in unresectable desmoplastic melanoma: the phase 2 SWOG S1512 trial.

Journal: Nature medicine

Published: August 26, 2025

Neoadjuvant PD-1 blockade in surgically resectable desmoplastic melanoma: cohort A of the phase 2 SWOG S1512 trial.

Neoadjuvant PD-1 blockade in surgically resectable desmoplastic melanoma: cohort A of the phase 2 SWOG S1512 trial.

Journal: Nature cancer

Published: July 10, 2025

Neoadjuvant Therapy: Changes in the Management of Macroscopic Stage III/Resectable Stage IV Melanoma.

Neoadjuvant Therapy: Changes in the Management of Macroscopic Stage III/Resectable Stage IV Melanoma.

Journal: Surgical oncology clinics of North America

Published: May 24, 2025

National Evaluation of the Management of Melanoma Patients with Multiple Positive Sentinel Lymph Nodes.

National Evaluation of the Management of Melanoma Patients with Multiple Positive Sentinel Lymph Nodes.

Journal: Annals of surgical oncology

Published: April 28, 2025

Anti-PD-1 therapy in unresectable desmoplastic melanoma: the phase 2 SWOG S1512 trial.

Anti-PD-1 therapy in unresectable desmoplastic melanoma: the phase 2 SWOG S1512 trial.

Journal: Nature medicine

Published: March 15, 2025

Tattooing and risk of melanoma: a population-based case-control study in Utah.

Tattooing and risk of melanoma: a population-based case-control study in Utah.

Journal: Journal of the National Cancer Institute

Published: March 12, 2025

Phase I and II Clinical Studies of the STING Agonist Ulevostinag with and without Pembrolizumab in Participants with Advanced or Metastatic Solid Tumors or Lymphomas.

Phase I and II Clinical Studies of the STING Agonist Ulevostinag with and without Pembrolizumab in Participants with Advanced or Metastatic Solid Tumors or Lymphomas.

Journal: Clinical cancer research : an official journal of the American Association for Cancer Research

Published: November 06, 2024

Showing 1-12 of 68

Last Updated: 09/26/2026